These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25323935)

  • 1. Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases.
    Akudugu J; Serafin A; Böhm L
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):627-31. PubMed ID: 25323935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.
    Böhm L; Serafin A; Akudugu J; Fernandez P; van der Merwe A; Aziz NA
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1221-8. PubMed ID: 23595126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of freeze-drying on the recovery of the tumour invasion markers uPA and PAI-1 from prostate cancer resections.
    Serafin AM; Akudugu JM; Bohm L
    Ann Clin Biochem; 2015 May; 52(Pt 3):387-94. PubMed ID: 25355777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The malignancy index is a robust predictor of prostate cancer.
    Serafin AM; Chinhengo A; Akudugu JM
    Discov Med; 2020; 29(158):181-189. PubMed ID: 33007193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
    Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
    Eur J Cancer; 1998 Jul; 34(8):1193-7. PubMed ID: 9849478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
    Kimura S; D'Andrea D; Iwata T; Foerster B; Janisch F; Parizi MK; Moschini M; Briganti A; Babjuk M; Chlosta P; Karakiewicz PI; Enikeev D; Rapoport LM; Seebacher V; Egawa S; Abufaraj M; Shariat SF
    World J Urol; 2020 Oct; 38(10):2501-2511. PubMed ID: 31797075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
    Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
    J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA; Edwards AB; Wittliff JL
    J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
    Schmitt M; Sturmheit AS; Welk A; Schnelldorfer C; Harbeck N
    Methods Mol Med; 2006; 120():245-65. PubMed ID: 16491606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
    Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
    Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
    Baker EA; Bergin FG; Leaper DJ
    Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
    Solberg A; Holmdahl L; Falk P; Willén R; Palmgren I; Ivarsson ML
    Scand J Gastroenterol; 2009; 44(5):579-84. PubMed ID: 19153874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
    Pappot H; Pedersen AN; Brünner N; Christensen IJ
    Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.